Nephros receives FDA 510(k) clearance for second-generation HDF Assist Module for hemodiafiltration therapy

NEPHROS INC

First and only FDA-cleared device in the US to provide hemodiafiltration therapy to ESRD patients.
Enables existing hemodialysis machines to perform HDF without costly new equipment.
Majority-owned subsidiary Specialty Renal Products to pilot device in select clinics.
No financial impact or revenue guidance change disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.